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ABSTRACT 
OBJECTIVE: The objective of this systematic review is to determine whether or not probiotics 
are effective at reducing the symptoms of asthma in children ages birth to twelve-years old. 
STUDY DESIGN: Review of three English-language, double-blinded randomized controlled 
trials (RCTs) from 2010 and 2011. 
DATA SOURCES: Three peer-reviewed RCTs were found using PubMed database. These 
studies compared probiotics to placebos in patients with episodes of wheezing.  
OUTCOMES MEASURED: Reduction in symptoms of asthma (particularly wheezing) 
measured with the use of diary cards and symptom scores.  
RESULTS: Chen et al. demonstrated statistically significant improvement in daytime asthma 
symptoms in probiotic treated versus placebo treated children age 6–12 years, with a p value of 
0.01. Rose et al found no statistically significant difference in asthma related symptoms between 
probiotic and placebo groups in children age 6–24 months. A Mann-Whitney U-test was used to 
determine this fact, using a 95% confidence interval. No test statistic was given. Van der Aa 
found that a synbiotic mixture containing a probiotic to reduce wheezing and/or noisy breathing 
apart from colds compared to placebo. This reduction was statistically significant, with a 95% 
confidence interval and a p value of 0.001.  
CONCLUSIONS: These results suggest that probiotics are effective at reducing asthma 
symptoms such as wheezing. Two of the three studies suggested statistically significant 
improvement in probiotic treated versus control groups.  
KEY WORDS: probiotics, asthma, wheezing.  
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INTRODUCTION 
 Asthma is a chronic inflammatory airway disorder characterized by episodic wheezing, 
difficulty breathing, chest tightness, and cough.1 While the exact cause of this disorder is 
unknown, there are several risk factors that have been identified. These include obesity, 
allergens, environmental irritants such as tobacco smoke, and precipitating factors such as 
exercise, respiratory tract infections, gastroesophageal reflux, and medications such as aspirin, 
among others. The strongest identified predisposing factor, however, is atopy- a genetic tendency 
to develop allergic disease.1 
 Asthma is a common disease, affecting approximately 7-10% of the population.1 In 2009, 
this percentage accounted for 24.6 million Americans.2 Because it affects so many individuals, 
the costs of this disorder are also significant. The total medical expenditures were estimated to be 
$62.8 billion in the United States in 2009.2 In addition, asthma can vary in severity; a severe 
exacerbation can be life-threatening, requiring hospitalization and significant medical attention. 
Each year, asthma accounts for roughly 500,000 hospital admissions and 4,500 deaths in the 
United States. Furthermore, over the past twenty years in the United States, the prevalence of, 
hospitalizations for, and fatalities due to asthma have all increased.1  
 As it can be seen, asthma is a significant disorder and thus is important to understand. 
Much research has been done and a lot is known about asthma. It is known that asthma is an 
inflammatory airway disorder. Inflammatory cells, such as eosinophils, neutrophils, and 
lymphocytes (especially T lymphocytes), infiltrate the mucosa of the lower airways.1 Goblet cell 
hyperplasia is also seen, leading to increase mucus production. The excess mucus can cause 
plugging of the small airways.1 Bronchial smooth muscle hypertrophy and mucosal edema may 
be present, leading to further obstruction and narrowing of the airways.1 These pathologic 
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changes to the airway, if significant, will lead to symptoms, including dyspnea, wheezing, and 
chest tightness. These symptoms may vary in frequency and severity, ranging from brief 
infrequent occurrences to almost continuous symptoms.1 
 While there is quite a bit that is known about asthma, there is other information that has 
yet to be discovered. For instance, the exact cause of asthma is unknown. As discussed above, 
many risk factors and predisposing features are associated with asthma, the strongest of which is 
atopy. However, the exact trigger to begin this inflammatory process is not completely 
understood. Additionally, the severity of inflammation is not always correlated with the severity 
of symptoms. It is not yet known, then, what can account for this discrepancy.3  
 Due to the extensive research of the pathogenesis of asthma, there are many treatment 
options aimed at combating these processes to reduce symptoms. The gold standard of treatment 
is not necessarily one medication; instead, a stepwise approach is often applied. All patients are 
given a short-acting beta-2-agonist (SABA), such as albuterol. These agents are intended to be 
used as needed in the event of an asthma attack, when prompt control is necessary.1 For 
persistent asthma, an inhaled corticosteroid (ICS) is first line. These agents, such as budesonide, 
work at reducing both acute and chronic inflammation.1 If the ICS alone does not control the 
patient’s asthma, the dose can be adjusted or a long-acting beta-2-agonist (LABA) may be 
added.1 A LABA, such as formoterol, works at long term prevention of asthma symptoms.1 
Further treatment may be required when prompt control of asthma is needed in the event of a 
severe attack; in this case, systemic corticosteroids are often used.1 Additionally, several agents 
have been developed with the intention of preventing further pathologic changes and thus at 
preventing asthma. These include leukotriene modifiers, mast cell activators, and agents like 
Omalizumab, which works based on the allergic nature of asthma.1 
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 This allergic nature of asthma is precisely what this review  is aimed at investigating. One 
hypothesis for the increasing prevalence of asthma is related to the hygiene hypothesis, which 
states that diminished microbial exposure in today’s society of avid hand washing and 
antimicrobial hand sanitizer use has led to an altered intestinal micro biota (which is believed to 
account for a significant part of human immunity).6 Therefore, the three randomized controlled 
trials (RCTs) reviewed in this paper examine asthma symptom reduction by increasing 
colonization of intestinal micro-organisms through the use of probiotics given to young 
children.6 Because atopy is noted to be the most important predisposing factor in the 
development of asthma, the implications of a method that targets the allergic nature of the 
disorder are significant.  
OBJECTIVE 
 The objective of this systematic review is to determine whether or not probiotics are 
effective at reducing the symptoms of asthma in children ages birth to twelve-years old.  
METHODS 
 Specific criteria were used when selecting the studies for this review. The populations 
examined were limited to children younger than twelve years old with diagnosed asthma or 
diagnosed episodes of wheezing. All studies included an intervention of probiotics; these 
included Lactobacillus gasseri, Lactobacillus rhamnosus, and a synbiotic containing the 
probiotic Bifidobacterium breve. In these studies, the experimental groups receiving the 
probiotics were compared to a control group receiving a visually matched placebo. The outcomes 
measured were reduction in the symptoms of asthma. The three studies classified symptoms of 
asthma in various ways, but this review will focus on the symptom of wheezing. Wheezing was 
evaluated either by rating severity on a scale of 1-4 or by tracking symptom severity with the use 
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of diary cards. All three studies included in this review are double-blind placebo-controlled 
randomized clinical trials (RCTs).  
 Key words used in searches to find these three studies included “asthma,” “probiotics,” 
and “children.” All articles were published in English and in peer reviewed journals. They were 
researched by the author using the PubMed database. These articles were selected based on their 
relevance to the clinical question and that the outcomes measured were patient oriented. 
Inclusion criteria included studies that were randomized controlled trials published after 2007, 
that included subjects less than 12 years old and had asthma or episodes of wheezing. Exclusion 
criteria comprised studies with patients older than 12 years of age and articles that focused 
exclusively on disease oriented evidence, such as IgE levels or spirometry.  The statistics that 
were used and reported are RRR, ARRR, RBI, ABI, NNT, p-value, and CI.  
 
 
Table 1- Demographics and Characteristics of Included Studies 
 
Study Type # 
Pts 
Age Inclusion Criteria Exclusion 
Criteria 
W/
D 
Interventions 
Chen et 
al., 2010  
RTC 118 6-
12 
yrs 
Age 6-12 years 
with a history of 2 
or more episodes 
of wheezing within 
the last 6 months 
and diagnosed 
mild-moderate 
persistent asthma. 
Persistent AR 
diagnosed for four 
or more days per 
week and for more 
than 4 weeks prior 
to the recruitment 
of the patients. 
 
Pts previously 
treated with 
immunotherapy, 
oral or parenteral 
corticosteroids  
administered for 
more than 15 
consecutive days 
or inhaled β2-
agonists more 
than 4 times a 
day  
Suffering from 
other respiratory 
diseases 
 
11 Lactobacillus 
gasseri 
1 capsule 
twice a day x 
8wks 
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Study Type # 
Pts 
Age Inclusion Criteria Exclusion 
Criteria 
W/
D 
Interventions 
Rose et 
al., 2010  
RTC 131 6 -
24 
mo 
a history of at least 
two physician-
diagnosed 
episodes of 
wheezing (≥3 
days, necessitating 
β2-bronchodilators 
or steroids) during 
the past 12 months 
 
at least one of 
these 
exacerbations in 
the 3 months 
immediately 
before enrolment  
 
a first-degree 
family history of 
atopic disease 
 
preterm birth 
(<37 weeks of 
gestational age) 
congenital 
malformations 
systemic 
disorders and 
chronic diseases 
current 
antibiotic 
therapy 
prior exposure 
to and known 
intolerances 
towards 
ingredients of 
probiotics 
 
29 Lactobacillus 
rhamnosus 
Capsules 
twice daily x 
6 mo 
Van der 
Aa et 
al., 2011  
RTC 90 < 7 
mo  
SCORing Atopic 
Dermatitis 
(SCORAD) score 
>15 
exclusive formula 
feeding at time of 
enrolment 
 
other major 
medical 
problems  
use of 
probiotics or 
immunomodulat
ory medication 
during the 
4 weeks before 
enrolment 
 
15 Synbiotic 
containing 
Bifidobacteri
um breve 
 
Given in an 
whey-based 
formula x12 
wks 
 
OUTCOMES  
 The outcomes measured were wheezing and the severity of asthma symptoms. All studies 
used diary cards completed by the children’s parents. In two of the three studies, the number of 
wheezing episodes per day and the number of days with a wheeze were recorded on the diary 
cards in order to assess severity.5,6 One of the three studies had parents complete diary cards 
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documenting asthmatic scores and rating asthma symptoms on a 4 point scale, such that 0= no 
symptoms, 1= mild symptoms, 2= moderate symptoms, and 3= severe symptoms.4  
RESULTS 
 Three randomized controlled trials evaluated the effect of probiotics on symptoms of 
asthma. All three studies examined these effects in children younger than 12 years old; two of 
these studies included infants (< 7 months and 6–24 months) and the third studied children age 
6–12 years. Additional inclusion criteria can be found in Table 1. The studies also set exclusion 
criteria, such as concurrent medical disorders, especially other respiratory disorders, and recent 
asthma medication use, among others (Table 1).4,6 These criteria help to eliminate confounding 
variables when analyzing the data results, such that wheezing and wheeze reduction could not be 
attributed to other factors.  
 None of these studies reported issues with patient compliance in taking probiotics. All 
studies lost some participants to follow up, however. In Chen et al, there was a 9.5% drop out 
rate, 17% in Van der Aa, and 22% in Rose et al. The latter is a relatively high rate and may have 
an influence on validity of results. However, in all three studies, an intention to treat analysis was 
completed.  
 In the Chen et al double-blind, randomized, placebo-controlled study, children age 6–12 
years old with mild persistent asthma were enrolled. A computer randomization schedule was 
made placing all participants into either the probiotic treated (55) or placebo group (61). Patients 
in the treatment group received one capsule of L. gasseri twice a day and the control group 
received a placebo capsule (containing milk powder) twice a day, for eight weeks. Every two 
weeks, participants’ clinical symptoms were evaluated by a physician. Patients also kept 
symptom diary cards which rated symptoms on a 4 point scale (explained above). A paired t-test 
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was used to assess changes from baseline, with a p-value below 0.05 considered significant. Of 
the 116 patients that were allocated to study groups, 105 were analyzed (9.5% loss to follow 
up).4  
A statistically significant improvement rate was found in the probiotic treated group for 
daytime asthmatic symptoms. Of the probiotic treatment group, 37 out of 49 reported 
improvement in daytime asthmatic symptoms, an experimental event rate (EER) of 75.5%. The 
placebo group had a control event rate (CER) of 62.5% (Table 2). This is a statistically 
significant difference, with a p-value of 0.01. This result has a relative benefit increase (RBI) of 
20.8% and an absolute benefit increase (ABI) of 13% (Table 2). The number needed to treat 
(NNT) is 8; thus, for every 8 patients given probiotics, 1 more will have improvement in daytime 
asthma symptoms than placebo, over 8 weeks (Table 2).4 
Table 2- Treatment Effect of L. gasseri on Daytime Asthma Symptoms 
CER EER RBI ABI NNT p-value 
62.5% 75.5% 20.8% 13% 8 0.01 
 
 In the Rose et al study, children age 6–24 months were recruited from a walk-in clinic 
over the course of a year (to exclude seasonal selection bias). Patients were observed for three 
months to confirm selection criteria, and then randomly assigned to a placebo (66 children) or 
experimental (65 children) group. The experimental group received L. rhamnosus capsules twice 
a day for six months. These capsules were matched to the placebo for size, shape, and volume. 
The probiotic was given in a double-blind matter. Patients were clinically monitored for one 
year. Asthma severity was assessed with symptom diaries kept by parents that recorded episodes 
of asthmatic exacerbations, including wheeze. Statistical analysis was done using the Mann-
Sulat, Probiotics and Asthma 8 
 
Whitney U-test for normally distributed variables on asthma related events, such as days with 
wheeze. The authors do not give a test statistic, but they state that the test revealed no statistical 
significance. Median values are given +/- a 95% confidence interval, such that p < 0.05 is 
considered statistically significant. For “days with wheeze” during the six month follow up 
period after intervention had taken place, patients in the probiotic group had a median of 8 days 
and patients in the placebo group had a median of 11 days with a wheeze. However, as 
previously stated, this was not found to be statistically significant.5 Additionally, in certain 
subgroups analyzed, it was even found that the treatment group had statistically significant lower 
asthma symptom scores.5 
 The van der Aa et al. study was a randomized double-blind study. Participants were 
ninety full-term infants < 7 months old. These infants were randomized using computer 
generated lists to receive either a hydrolyzed whey-based formula containing a synboitic 
(combination of probiotic Bifidobacterium breve and short-chain galactooligosaccharides and 
long chain fructooligosaccharides) (46 infants) or the same formula without the synbiotic (44 
infants). The formula was given on demand, for a period of 12 weeks. Participants followed-up 
one year after the start of the study, at which time parents were asked about respiratory 
symptoms and medication use through the use of a validated questionnaire.6 
 Analysis of all data was done with an unpaired t-tests for parametric data, and the Mann-
Whitney U-test for nonparametric data. The analysis showed that “wheezing and noisy/rattly 
breathing apart from colds”6 was significantly less prevalent in the synbiotic treated group 
compared with the placebo group. Because this study involved infants that did not yet have a 
diagnosis of asthma, the results reflect a prevention effect rather than treatment. At the time of 
follow up, the experimental event rate (EER) was 2.8%, and the control event rate (CER) was 
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30.8%. This translates to a relative risk reduction (RRR) of – 91% and an absolute risk reduction 
(ARR) of -28% and thus a NNT of -3 (Table 3). This means that 3 patients would need to use 
this synbiotic formula in order to prevent one less instance of wheezing/noisy breathing apart 
from colds. The p-value for this data is 0.001 with a 95% confidence interval. Because the NNT 
is low and the p-value is <0.05, this demonstrates that the synbiotic was effective at preventing 
wheezing in a statistically significant manner.6  
Table 3- Prevention of Wheezing and Noisy/Rattly Breathing Apart from Colds 
CER EER RRR ARR NNT 95% CI  
 (-43.4 to -12.5 
for ARR) 
30.8%  2.8%  -0.91 -0.28 -3 p-value= 0.001  
 
 
DISCUSSION 
 This systematic review analyzed three RCTs to determine if probiotics were effective at 
reducing symptoms of asthma, particularly wheezing. One of these three studies showed no 
improvement in asthma symptoms.5 The other two demonstrated statistically significant 
reduction in wheezing;4,6 however they did so in specific circumstances that may not be 
applicable universally. Therefore, additional research is needed before strong recommendations 
for this patient population can be made. 
 Probiotics have been used as adjunctive treatment is several other disorders of the 
intestinal tract, such as infectious diarrhea, irritable bowel syndrome, H. pylori infection, C. 
difficile infection, and preventions of vulvovaginal candidiasis. As such, several products are 
readily available in the United States.7 However, these are all off-label indications; the FDA has 
not approved probiotics for any therapeutic indications. Probiotics are classified as dietary 
supplements, and therefore do not require FDA approval for use as such.8  
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 There are some standard contraindications and warnings associated with probiotics, as 
there are with any medical intervention. Patients with a hypersensitivity to microorganisms, or to 
lactose or milk, should not take probiotics.7 Also, they should not be used in 
immunocompromised patients, patients with central venous catheters, or patients with a high 
fever.7  
 Since probiotics are readily available with few contraindications, the findings of this 
systematic review can be useful for patient populations fitting the criteria of the clinical question. 
However, there are other limitations of the studies reviewed to consider. In Chen et al., patients 
continued to use asthma medications throughout the study. Although this occurred in both 
experimental and control groups, and researchers attempted to account for it with the use of 
medication record scores, it still must be considered.4 Additionally, the authors point out that any 
research regarding allergic disease and probiotics may have varied results due to variations in 
host factors such as genetic predisposition, and environmental factors such as diet and individual 
microflora.4 Randomization helps limit the effect of such variables but cannot eliminate them 
completely.  
 Rose et al. found no beneficial effect of probiotics on asthmatic symptoms. Some 
limitations of this study were that the results relied on caretakers’ evaluation of the children’s 
symptoms on diary cards, since the children were 6–24 months of age.5 Additionally, by chance, 
the randomization placed a statistically significant greater amount of children experiencing more 
than 5 episodes of wheezing per year, as well as more children with household exposure to 
cigarette smoke, into the experimental vs the control group.5 This may have skewed the data. 
Lastly, as previously mentioned, there was a loss to follow up of 22%.5 This too may affect the 
results of the study and brings to question the reliability of the findings.  
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 In the van der Aa study, one limitation for this systematic review is that this investigation 
examined a probiotic that was included as part of a synbiotic mixture containing additional 
prebiotic components;6 this is therefore a confounding variable and complicates the application 
of the results to the probiotic’s effect alone. This study too relied on parents completing diary 
cards, and they may have misunderstood the term “wheeze.”6 However this is likely to have 
occurred in both groups and thus is not likely to be substantially influence the results.   
CONCLUSION 
 This review has shown probiotics to be effective at reducing asthma symptoms. Majority 
(two of three) of studies showed reduction; however the third failed to, and even saw worse 
symptoms in the probiotic group than in the placebo group. Additionally, other factors 
complicate the data analysis, such as the concurrent use of a prebiotic in the van der Aa study 
and the statistically significant difference in wheeze before probiotics in the Rose et al. study. 
Therefore, further research needs to be done before probiotics should be considered as a means 
of prevention or treatment of asthma symptoms such as wheeze. This research may include 
studies that examine exclusively probiotics, and most optimally the same strain of bacteria; for 
instance, several studies examining only the effect of one Lactobacillus strain would be of more 
use. If these studies were to continue to show probiotics as effective, additional studies 
comparing Lactobacillus versus Bifidobacterium would also be of interest. Regardless, the 
involvement of microflora in the development of allergic disease appears to have validity and is 
an intriguing area of continued investigation.  
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